Alexia Almaraz-Arreortua
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Alexia Almaraz-Arreortua has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
- Honorio Torres-Aguilar
Facultad de Ciencias Químicas, Universidad Autónoma “Benito Juárez” de Oaxaca, Oaxaca 68120, México
3 shared publications - Sorely Adelina Sosa-Luis
Benito Juárez Autonomous University of Oaxaca, Department of Basic and Clinical Immunology Research, Faculty ofBiochemical Sciences, Av. Universidad S/N, Ex-Hacienda 5 Señores, Oaxaca City, Mexico
3 shared publications - William de Jesús Ríos-Ríos
Benito Juárez Autonomous University of Oaxaca, Faculty of Dentistry, Av. Universidad S/N, Ex-Hacienda 5 Señores, Oaxaca City, Mexico
3 shared publications - María de Los Ángeles Romero-Tlalolini
Facultad de Medicina y Cirugía, UABJ (Universidad Autónoma Benito Juárez de Oaxaca), Oaxaca 68120, Mexico
2 shared publications - Sergio Roberto Aguilar-Ruiz
Facultad de Medicina y Cirugía, Universidad Autónoma “Benito Juárez” de Oaxaca, Oaxaca 68120, Mexico
2 shared publications - Carmen Sánchez-Torres
Centro de Investigación en Sanidad Animal, INIA, Valdeolmos, Madrid, Spain
1 shared publication
Latest Publications
- 21 August 2026
- Published by Bentham Science Publishers Ltd. in Current Stem Cell Research & Therapy
- Vol. 21, 1-14
Conditioned Medium from IFNγ-Pretreated Human Gingival Mesenchymal Stromal Cells Enhances the Immunomodulatory Effects on Neutrophils
Introduction/ Objective: Neutrophils are crucial for an effective innate immune response. However, overactivation is associated with chronic inflammation, as in systemic lupus erythematosus (SLE). Gingival mesenchymal stromal cells (GMSCs) are used as anti-inflammatory therapies because they possess strong immunomodulatory properties, primarily acting through paracrine mechanisms. GMSCs exhibit immunoplasticity in response to their microenvironment and adjust their secretion profile. This study aimed to investigate the effects of conditioned media derived from human gingival mesenchymal stromal cells (hGMSC-CM) or from cells pretreated with IFNγ (hGMSCγ- CM) on neutrophil antimicrobial and proinflammatory functions. Methods: hGMSCs were isolated to meet the criteria of the International Society for Cell & Gene Therapy (ISCT). Neutrophil intracellular reactive oxygen species (ROS) production; neutrophil elastase (NE), cathepsin G (CG), and myeloperoxidase (MPO) enzymatic activities; induction of lytic and vital neutrophil extracellular traps (NETs); and bacterial uptake and engulfment were analyzed using flow cytometry, photometric methods, and fluorescence and confocal microscopy. Results: Both hGMSC-derived CMs significantly reduced intracellular ROS levels, reduced the enzymatic activities of MPO, CG, and NE by decreasing degranulation, and diminished NET formation (DNA, LL37, and PAD4) through both the lytic and vital pathways, including NET production observed in an inflammatory environment using plasma from SLE patients. Discussion: These inhibitory effects were more pronounced with hGMSCγ-CM. Interestingly, hGMSCγ-CM did not impair bacterial uptake, engulfment, or neutrophil microbicidal activity against Staphylococcus aureus and Escherichia coli, thereby maintaining the functional balance of neutrophils. Conclusion: These findings support the use of hGMSCγ-CM as a cell-free biological product for therapies targeting inflammation driven by neutrophil overactivation.
- 21 August 2026
- Published by Bentham Science Publishers Ltd. in Current Stem Cell Research & Therapy
- Vol. 21, 1-14
Conditioned Medium from IFNγ-Pretreated Human Gingival Mesenchymal Stromal Cells Enhances the Immunomodulatory Effects on Neutrophils
Introduction/ Objective: Neutrophils are crucial for an effective innate immune response. However, overactivation is associated with chronic inflammation, as in systemic lupus erythematosus (SLE). Gingival mesenchymal stromal cells (GMSCs) are used as anti-inflammatory therapies because they possess strong immunomodulatory properties, primarily acting through paracrine mechanisms. GMSCs exhibit immunoplasticity in response to their microenvironment and adjust their secretion profile. This study aimed to investigate the effects of conditioned media derived from human gingival mesenchymal stromal cells (hGMSC-CM) or from cells pretreated with IFNγ (hGMSCγ- CM) on neutrophil antimicrobial and proinflammatory functions. Methods: hGMSCs were isolated to meet the criteria of the International Society for Cell & Gene Therapy (ISCT). Neutrophil intracellular reactive oxygen species (ROS) production; neutrophil elastase (NE), cathepsin G (CG), and myeloperoxidase (MPO) enzymatic activities; induction of lytic and vital neutrophil extracellular traps (NETs); and bacterial uptake and engulfment were analyzed using flow cytometry, photometric methods, and fluorescence and confocal microscopy. Results: Both hGMSC-derived CMs significantly reduced intracellular ROS levels, reduced the enzymatic activities of MPO, CG, and NE by decreasing degranulation, and diminished NET formation (DNA, LL37, and PAD4) through both the lytic and vital pathways, including NET production observed in an inflammatory environment using plasma from SLE patients. Discussion: These inhibitory effects were more pronounced with hGMSCγ-CM. Interestingly, hGMSCγ-CM did not impair bacterial uptake, engulfment, or neutrophil microbicidal activity against Staphylococcus aureus and Escherichia coli, thereby maintaining the functional balance of neutrophils. Conclusion: These findings support the use of hGMSCγ-CM as a cell-free biological product for therapies targeting inflammation driven by neutrophil overactivation.
- Open Access
- 30 June 2025
- Published by Open Exploration Publishing in Exploration of Immunology
- Vol. 5, 1003201
Harnessing monocyte-derived dendritic cells for evaluating T cell response by mixed leukocyte reaction
The mixed leukocyte reaction (MLR) is a pivotal in vitro assay for evaluating T-cell responses stimulated by allogeneic antigen-presenting cells (APCs). Dendritic cells (DCs) are the most efficient stimulatory cells. However, the scarcity of circulating DCs in peripheral blood limits their isolation for research or clinical use. In contrast, monocytes, which are abundant and easily accessible, can be differentiated into monocyte-derived DCs (moDCs) in vitro and have emerged as the most practical and efficient stimulatory cells for MLR due to their accessibility and robust allostimulatory capabilities. This review aims to describe the scientific rationale and evidence for using moDCs in MLR assays to assess T-cell alloreactivity. Its methodology outlines the protocols for experimental, preclinical, and biosafety assays that have demonstrated the practicality of moDCs in evaluating and quantifying the alloresponse of naïve and memory CD4+ and CD8+ T cells, as well as the effects of immunomodulatory factors, immune monitoring, and tolerogenic strategies in the context of transplantation. Additionally, it illustrates how moDC-mediated MLRs have provided critical insights into understanding alloimmunity processes and antigen-specific T-cell responses in cancer immunotherapy, autoimmune diseases, and vaccine development, with potential implications for personalized medicine and immunotherapy optimization. In conclusion, despite ongoing challenges such as standardization and scalability in massive cell production, the current understanding and reproducible results of moDC applications in MLRs highlight their potential to develop innovative strategies focused on immune monitoring.
- 30 June 2025
- Published by Open Exploration Publishing in Exploration of Immunology
- Vol. 5, 1003201
Open AccessHarnessing monocyte-derived dendritic cells for evaluating T cell response by mixed leukocyte reaction
The mixed leukocyte reaction (MLR) is a pivotal in vitro assay for evaluating T-cell responses stimulated by allogeneic antigen-presenting cells (APCs). Dendritic cells (DCs) are the most efficient stimulatory cells. However, the scarcity of circulating DCs in peripheral blood limits their isolation for research or clinical use. In contrast, monocytes, which are abundant and easily accessible, can be differentiated into monocyte-derived DCs (moDCs) in vitro and have emerged as the most practical and efficient stimulatory cells for MLR due to their accessibility and robust allostimulatory capabilities. This review aims to describe the scientific rationale and evidence for using moDCs in MLR assays to assess T-cell alloreactivity. Its methodology outlines the protocols for experimental, preclinical, and biosafety assays that have demonstrated the practicality of moDCs in evaluating and quantifying the alloresponse of naïve and memory CD4+ and CD8+ T cells, as well as the effects of immunomodulatory factors, immune monitoring, and tolerogenic strategies in the context of transplantation. Additionally, it illustrates how moDC-mediated MLRs have provided critical insights into understanding alloimmunity processes and antigen-specific T-cell responses in cancer immunotherapy, autoimmune diseases, and vaccine development, with potential implications for personalized medicine and immunotherapy optimization. In conclusion, despite ongoing challenges such as standardization and scalability in massive cell production, the current understanding and reproducible results of moDC applications in MLRs highlight their potential to develop innovative strategies focused on immune monitoring.
- 14 April 2023
- Published by Springer Nature in Purinergic Signalling
- Vol. 20 (1) , 73-82
Human plasmacytoid dendritic cells express the functional purinergic halo (CD39/CD73)
Plasmacytoid dendritic cells (pDCs) are a specialized DC subset mainly associated with sensing viral pathogens and high-type I interferon (IFN-I) release in response to toll-like receptor (TLR)-7 and TLR-9 signaling. Currently, pDC contribution to inflammatory responses is extensively described; nevertheless, their regulatory mechanisms require further investigation. CD39 and CD73 are ectoenzymes driving a shift from an ATP-proinflammatory milieu to an anti-inflammatory environment by converting ATP to adenosine. Although the regulatory function of the purinergic halo CD39/CD73 has been reported in some immune cells like regulatory T cells and conventional DCs, its presence in pDCs has not been examined. In this study, we uncover for the first time the expression and functionality of the purinergic halo in human blood pDCs. In healthy donors, CD39 was expressed in the cell surface of 14.0 ± 12.5% pDCs under steady-state conditions, while CD73 showed an intracellular location and was only expressed in 8.0 ± 2.2% of pDCs. Nevertheless, pDCs stimulation with a TLR-7 agonist (R848) induced increased surface expression of both molecules (43.3 ± 23.7% and 18.6 ± 9.3%, respectively), as well as high IFN-α secretion. Furthermore, exogenous ATP addition to R848-activated pDCs significantly increased adenosine generation. This effect was attributable to the superior CD73 expression and activity because blocking CD73 reduced adenosine production and improved pDC allostimulatory capabilities on CD4 + T cells. The functional expression of the purinergic halo in human pDCs described in this work opens new areas to investigate its participation in the regulatory pDC mechanisms in health and disease.
- 14 April 2023
- Published by Springer Nature in Purinergic Signalling
- Vol. 20 (1) , 73-82
Human plasmacytoid dendritic cells express the functional purinergic halo (CD39/CD73)
Plasmacytoid dendritic cells (pDCs) are a specialized DC subset mainly associated with sensing viral pathogens and high-type I interferon (IFN-I) release in response to toll-like receptor (TLR)-7 and TLR-9 signaling. Currently, pDC contribution to inflammatory responses is extensively described; nevertheless, their regulatory mechanisms require further investigation. CD39 and CD73 are ectoenzymes driving a shift from an ATP-proinflammatory milieu to an anti-inflammatory environment by converting ATP to adenosine. Although the regulatory function of the purinergic halo CD39/CD73 has been reported in some immune cells like regulatory T cells and conventional DCs, its presence in pDCs has not been examined. In this study, we uncover for the first time the expression and functionality of the purinergic halo in human blood pDCs. In healthy donors, CD39 was expressed in the cell surface of 14.0 ± 12.5% pDCs under steady-state conditions, while CD73 showed an intracellular location and was only expressed in 8.0 ± 2.2% of pDCs. Nevertheless, pDCs stimulation with a TLR-7 agonist (R848) induced increased surface expression of both molecules (43.3 ± 23.7% and 18.6 ± 9.3%, respectively), as well as high IFN-α secretion. Furthermore, exogenous ATP addition to R848-activated pDCs significantly increased adenosine generation. This effect was attributable to the superior CD73 expression and activity because blocking CD73 reduced adenosine production and improved pDC allostimulatory capabilities on CD4 + T cells. The functional expression of the purinergic halo in human pDCs described in this work opens new areas to investigate its participation in the regulatory pDC mechanisms in health and disease.